Antibody-drug Conjugate Information

General Information of This Antibody-drug Conjugate (ADC)
ADC ID
DRG0RCHSE
ADC Name
SKB-315
Synonyms
A315; SKB 315; SKB-315; SKB315
   Click to Show/Hide
Organization
KLUS Pharma, Inc.; Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
Drug Status
Phase 1
Indication
In total 1 Indication(s)
Solid tumor
Phase 1
Clinical Trial
Drug-to-Antibody Ratio
7 to 8
Antibody Name
Undisclosed
Antigen Name
Claudin-18.2 (CLDN18.2)
  Antigen Info 
Payload Name
Topoisomerase I inhibitor
  Payload Info 
Therapeutic Target
DNA topoisomerase 1 (TOP1)
  Target Info 
Conjugate Type
Random Cysteines
General Information of The Activity Data Related to This ADC
Identified from the Human Clinical Data
Click To Hide/Show 1 Activity Data Related to This Level
Standard Type NCT Number Clinical Status Clinical Trial Description
Undisclosed  NCT05367635
Phase 1
A phase 1 clinical study to evaluate the safety, tolerability, pharmacokinetics and preliminary efficacy of SKB315 for injection in patients with advanced solid tumors expressing claudin 18.2.
Full List of Activity Data of This Antibody-drug Conjugate
Identified from the Human Clinical Data
Click To Hide/Show 1 Activity Data Related to This Level
Experiment 1 Reporting the Activity Date of This ADC [1]
Related Clinical Trial
NCT Number NCT05367635  Clinical Status Phase 1
Clinical Description A phase 1 clinical study to evaluate the safety, tolerability, pharmacokinetics and preliminary efficacy of SKB315 for injection in patients with advanced solid tumors expressing claudin 18.2.
References
Ref 1 A Phase 1 Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of SKB315 for Injection in Patients With Advanced Solid Tumors Expressing Claudin18.2